LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris

Exclusion Criteria

• •Systemic treatment with biological therapies, whether marketed or not, with a possible effect on psoriasis vulgaris within the following time periods prior to Visit 1:
• •* etanercept - within 4 weeks prior to Visit 1
• •* adalimumab, infliximab - within 8 weeks prior to Visit 1
• •* ustekinumab - within 16 weeks prior to Visit 1
• •* secukinumab - within 12 weeks prior to Visit 1
• •* other products - within 4 weeks/5 half-lives prior to Visit 1 (whichever is longer)
• •Systemic treatment with all other therapies with a possible effect on psoriasis vulgaris (e.g. corticosteroids, retinoids, methotrexate, ciclosporin and other immunosuppressants) within 4 weeks prior to Visit 1
• •Systemic treatment with apremilast within 4 weeks prior to Visit 1
• •Psoralen combined with Ultraviolet A (PUVA) therapy within 4 weeks prior to Visit 1
• •Ultraviolet B (UVB) therapy within 2 weeks prior to Visit 1
• •Severe and/or extensive scalp psoriasis which, in the opinion of the investigator, requires treatment with potent or super-potent corticosteroids which will be prohibited during the trial
• •For subjects participating in HPA-axis testing, furthermore:
• •Antidepressive medications within 4 weeks prior to Visit 1 or during the trial. Oestrogen therapy (including contraceptives), antidepressant medications and any other medication known to affect cortisol levels or HPA axis integrity within 4 weeks prior to baseline